Compare GFI & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFI | TEVA |
|---|---|---|
| Founded | 1887 | 1901 |
| Country | South Africa | Israel |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0B | 40.5B |
| IPO Year | 2002 | 1996 |
| Metric | GFI | TEVA |
|---|---|---|
| Price | $40.91 | $36.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $52.71 | $38.63 |
| AVG Volume (30 Days) | 3.2M | ★ 5.4M |
| Earning Date | 03-30-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | N/A | ★ 183.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.67 | N/A |
| Revenue Next Year | N/A | $2.97 |
| P/E Ratio | $25.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.24 | $17.33 |
| 52 Week High | $61.52 | $37.39 |
| Indicator | GFI | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 66.20 | 66.85 |
| Support Level | $38.14 | $30.42 |
| Resistance Level | $41.27 | $37.17 |
| Average True Range (ATR) | 1.09 | 0.95 |
| MACD | 0.63 | 0.25 |
| Stochastic Oscillator | 87.81 | 88.53 |
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia, and Peru. In Peru, the company also produces copper. The company is involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing, and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith, and South Deep, and surface-only open pit mining at Damang, Tarkwa, and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.